Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery

Heart Surgery Forum

Volumn 16, Issue 2, 2013, Pages

  Firstenberg, Michael S ^a   Dyke, Cornelius M ^b   Angiolillo, Dominick J ^c   Ramaiahm, Chandrashekar ^d   Price, Matthew ^e   Brtko, Miroslav ^f   Welsby, Ian ^g   Chandna, Harish ^h   Holmes, David R ⁱ   Voeltz, Michele ^b   Tummala, Pradyumna ^j   Hutyra, Martin ^k   Manoukian, Steven V ^l   Prats, Jayne ^m   Todd, Meredith ^m   Liu, Tiepu ^m   Chronos, Nicholas ⁿ   Dietrich, Markus ^m   Montalescot, Gilles ^o   Cannon, Louis A ^p   Topol, Eric J ^e   more..

^a NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^b Sanford Health Medical Center   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

^e SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE   (United States)

^f UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^g DUKE UNIVERSITY   (United States)

^h DeTar Hospital   (United States)

ⁱ MAYO CLINIC   (United States)

^j Northeast Georgia Heart Center   (United States)

^k UNIVERSITY HOSPITAL OLOMOUC   (Czech Republic)

^l SARAH CANNON RESEARCH INSTITUTE   (United States)

^m MEDICINES COMPANY   (United States)

ⁿ Saint JJoseph's Translational Research Institute   (United States)

^o PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^p Northern Michigan Hospital   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PRASUGREL; THIENOPYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PLATELET REACTIVITY; POINT OF CARE TESTING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

ADENOSINE MONOPHOSPHATE; ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BLOOD TRANSFUSION; CORONARY ARTERY BYPASS; DRUG THERAPY, COMBINATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLACEBO EFFECT; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE HEMORRHAGE; PREMEDICATION; PREVALENCE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; PYRIDINES; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 84877997976     PISSN: 10983511     EISSN: 15226662     Source Type: Journal    
DOI: 10.1532/HSF98.20121103     Document Type: Article

References (25)

1. Aguirre FV, Topol EJ, Ferguson JJ, et al, for the EPIC Investigators. 1995. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation 91:2882-90.
2. Angiolillo DJ, Firstenberg MS, Price MJ, et al, for the BRIDGE Investigators. 2012. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 307:265-74.
3. Bennett-Guerrero E, Slaughter TF, White WD, et al. 2005. Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. J Thorac Cardiovasc Surg 130:1567-72. (Pubitemid 41676920)
4. Bhatt DL, Lincoff AM, Gibson CM, et al, for the CHAMPION PLATFORM Investigators. 2009. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 361:2330-41.
5. Biancari F, Airaksinen KE, Lip GY. 2011. Benefits and risks of using clopidogrel before coronary artery bypass surgery: systematic review and meta-analysis of randomized trials and observational studies. J Thorac Cardiovasc Surg 143:665-75.e4.
6. Bonello L, Tantry US, Marcucci R, et al Working Group on High On-Treatment Platelet Reactivity. 2010. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 56:919-33.
7. Chen ZM, Jiang LX, Chen YP, et al COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. 2005. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366:1607-21.
8. Collet JP, Montalescot G, Blanchet B, et al. 2004. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation 110:2361-7. (Pubitemid 39407340)
9. Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC. 1983. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment. J Thorac Cardiovasc Surg 85:346-53. (Pubitemid 13093724)
10. Gao C, Boylan B, Fang J, Wilcox DA, Newman DK, Newman PJ. 2011. Heparin promotes platelet responsiveness by potentiating IIb 3-mediated outside-in signaling. Blood 117:4946-52.
11. Giugliano RP, White JA, Bode C, et al, for the EARLY ACS Investigators. 2009. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 360:2176-90.
12. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. 2003. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107:2908-13. (Pubitemid 36736631)
13. Harrington RA, Stone GW, McNulty S, et al. 2009. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 361:2318-29.
14. Lewis BS, Mehta SR, Fox KA, et al, for the CURE trial investigators. 2005. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Am Heart J 150:1177-84. (Pubitemid 41773519)
15. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V. 2006. Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find Exp Clin Pharmacol 28:315-22. (Pubitemid 44047198)
16. Marcucci R, Gori AM, Paniccia R, et al. 2009. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119:237-42.
17. Michelson AD. 2004. Platelet function testing in cardiovascular diseases. Circulation 110:489-93.
18. Nijjer SS, Watson G, Athanasiou T, Malik IS. 2011. Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. Eur Heart J 32:2970-88.
19. Norgard NB. 2009. Cangrelor: a novel P2Y12 receptor antagonist. Expert Opin Investig Drugs 18:1219-30.
20. Patti G, Nusca A, Mangiacapra F, Gatto L, D'Ambrosio A, Di Sciascio G. 2008. Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 52:1128-33.
21. Price MJ, Endemann S, Gollapudi RR, et al. 2008. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 29:992-1000. (Pubitemid 351844676)
22. Sabatine MS, Cannon CP, Gibson CM, et al, for the Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. 2005. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 352:1179-89. (Pubitemid 40397259)
23. Sambu N, Warner T, Curzen N. 2011. Clopidogrel withdrawal: is there a "rebound" phenomenon? Thromb Haemost 105:211-20.
24. Wright RS, Anderson JL, Adams CD, et al. 2011. ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy of Family Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 57:e215-367.
25. Yusuf S, Zhao F, Mehta SR, et al Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. 2001. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345:494-502. (Pubitemid 32758501)